1702259-66-2 Usage
Uses
Used in Oncology:
H3B-6527 is used as an anti-cancer agent for its ability to target the SF3b complex and disrupt the splicing process in cancer cells. This leads to the production of aberrant mRNA transcripts, ultimately inhibiting the growth of cancer cells and showing potential in the treatment of various forms of cancer.
Used in Hematologic Malignancies:
H3B-6527 is used as a therapeutic agent for the treatment of hematologic malignancies such as acute myeloid leukemia and myelodysplastic syndromes. Its selective inhibition of the SF3b complex has shown promising anti-cancer activity in preclinical studies, offering a new approach for targeting splicing abnormalities in these types of cancer cells.
Check Digit Verification of cas no
The CAS Registry Mumber 1702259-66-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,7,0,2,2,5 and 9 respectively; the second part has 2 digits, 6 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1702259-66:
(9*1)+(8*7)+(7*0)+(6*2)+(5*2)+(4*5)+(3*9)+(2*6)+(1*6)=152
152 % 10 = 2
So 1702259-66-2 is a valid CAS Registry Number.
1702259-66-2Relevant academic research and scientific papers
CRYSTALLINE FGFR4 INHIBITOR COMPOUND AND USES THEREOF
-
Page/Page column 33-34, (2016/11/02)
A number of crystalline forms of N-(2-((6-(3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-methylureido)pyrimidin-4-yl)amino)-5-(4-ethylpiperazin-1-yl)phenyl)acrylamide are provided. These include a crystalline free base form, a crystalline monohydrochloride salt
PYRIMIDINE FGFR4 INHIBITORS
-
, (2015/05/05)
Provided herein are compounds of Formula I useful as FGFR4 inhibitors, as well as methods of use of the same.
